علاج خط العلاج الأول للنقائل العظمية

References

DOI: 10.1007/s12094-016-1590-1

• Zoledronate or zoledronic acid (ZA), the most effective third-generation bisphosphonate in preventing SRE, is administered at a dose of 4 mg intravenous (iv) during 15 min every 3 (q3w) or 4 weeks (q4w), with supplemental calcium and vitamin D.
• It is recommended to start at the bone metastases diagnosis, even the patient is asymptomatic, and should be continued indefinitely during the disease.
• Denosumab is recommended to be administered at a dose of 120 mg as a single subcutaneous (sc) injection once every 4 weeks taking supplemental calcium and vitamin D.
• It is recommended to start its use at the bone metastases diagnosis and should be continued indefinitely during the disease.
• The proportion of SRE was 29.5 vs 28.6% (p = 0.79) for monthly and every 3 months, respectively, showing that zoledronic administered every 3 months is non-inferior to zoledronic administered monthly for 24 months.